Latest from Mayo Clinic Cancer Center

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses a phase I study of napabucasin plus nab-paclitaxel (Abraxane) and gemcitabine for the treatment of patients with pancreatic cancer.
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the results of the phase III IDEA project for patients with stage III colon cancer.
Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.
 
Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).
Publication Bottom Border
Border Publication